AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8087937
Drug: ATP‐MgCl2 (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATP‐MgCl2 (0.1 mg/kg/min)
Trial: 8087937
Drug: Tolazoline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolazoline (1 mg/kg)
Trial: 2503148
Drug: Postoperative radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative radiotherapy (orthovoltage treatment)
Trial: 361132
Drug: BCG immunotherapy
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG immunotherapy as an adjunct to surgery
Trial: 31779056
Drug: Full dose
RxNorm normalized name: BayRHo-D Full Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full dose of quadrivalent influenza vaccine
Trial: 31779056
Drug: Half dose
RxNorm normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half dose of trivalent influenza vaccine
Trial: 29851024
Drug: 8 mL/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mL/kg Ringer's acetate solution before the induction of anaesthesia
Trial: 18635722
Drug: Duloxetine 60-120
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60-120 mg/day
Trial: 1564540
Drug: Intravenous BCNU
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous BCNU
Trial: 1564540
Drug: Intravenous 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 5-fluorouracil
Trial: 3970647
Drug: Pindolol (dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol (dosage not specified)
Trial: 27843418
Drug: CHO ingestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO ingestion at 15 g/h
Trial: 27843418
Drug: CHO ingestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO ingestion at 60 g/h
Trial: 24238825
Drug: Topical tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical tranexamic acid (2 g)
Trial: 18814408
Drug: Phytotherapy (herbal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytotherapy (herbal medicine)
Trial: 16075255
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia (TIVA) using propofol/remifentanil
Trial: 12430113
Drug: Patient-Controlled Femoral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-Controlled Femoral Analgesia (PCFA) with 0.2% ropivacaine (boluses of 10 mL with a lockout time of 60 minutes)
Trial: 12430113
Drug: Continuous Femoral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Femoral Infusion (Inf) with 0.2% ropivacaine (10 mL/h)
Trial: 12430113
Drug: PCFA +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCFA + Inf with 0.2% ropivacaine (5 mL/h plus boluses of 5 mL with a lockout time of 60 minutes)
Trial: 28498207
Drug: No secondary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No secondary injection
Trial: 23748819
Drug: MA plus
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MA plus meloxicam plus oral eicosapentaenoic acid (EPA)-enriched nutritional supplement (n = 21)
Trial: 23748819
Drug: meloxicam plus
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: meloxicam plus oral EPA-enriched nutritional supplement (n = 18)
Trial: 20655544
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral treatment with peer-enhanced adventure therapy
Trial: 20655544
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral weight control treatment with supervised aerobic exercise
Trial: 18209781
Drug: 5-HTP 100
RxNorm normalized name: CVS 5-HTP 100mg Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-HTP 100 mg/day
Trial: 11906645
Drug: GM-CSF-stimulated peripheral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM-CSF-stimulated peripheral blood stem cell (PBSC) infusion with cyclosporin A (CsA) and 0.4 mg/kg prednisolone
Trial: 11906645
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received azathioprine, 1 mg/kg prednisolone, and CsA
Trial: 29982723
Drug: High-Intensity Sweeteners
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Intensity Sweeteners Beverage (HISB) - 2 cans (330 mL each)/d for 12 weeks
Trial: 29982723
Drug: Unsweetened Beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unsweetened Beverage (UB) - 2 cans (330 mL each)/d for 12 weeks
Trial: 20224007
Drug: Lactobacillus plantarum
RxNorm normalized name: Lactobacillus Plantarum
DrugBank: Lactobacillus plantarum (DB11360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus plantarum strain WCFS1 administered in the duodenum for 6 hours via feeding catheter
Trial: 20224007
Drug: TLR2 agonist
RxNorm normalized name: anti-Tlr2 monoclonal antibody OPN-305
DrugBank: Tomaralimab (DB15415)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TLR2 agonist Pam(3)‐Cys‐SK4 (PCSK)
Trial: 16389694
Drug: Exenatide (glucagon‐like
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide (glucagon‐like peptide‐1 agonist)
Trial: 11879382
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg LTG
Trial: 11879382
Drug: VPA 900
RxNorm normalized name: VPA
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: VPA 900 mg
Trial: 10229128
Drug: IgM antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgM antibodies to nerve glycoconjugates
Trial: 7887643
Drug: FP (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FP (400 mg/m2 UFT po daily and 50 mg/m2 CDDP i.v. on days 1 and 8 every 4 weeks)
Trial: 7887643
Drug: FEP (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEP (400 mg/m2 UFT po daily, 50 mg/m2 etoposide iv and 50 mg/m2 CDDP i.v. on days 1 and 8 every 4 weeks)
Trial: 2167953
Drug: Cisplatin (CDDP;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (CDDP; 120 mg/m2, day 1) plus etoposide (VP16; 100 mg/m2, days 1, 2, and 3)
Trial: 2167953
Drug: Carboplatin (CBDCA;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carboplatin (CBDCA; 325 mg/m2, day 1) plus etoposide (VP16; 100 mg/m2, days 1, 2, and 3)
Trial: 598412
Drug: Digoxin 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin 0.4 mg i.v. daily for 14 days
Trial: 598412
Drug: Beta-methyldigoxin 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-methyldigoxin 0.4 mg i.v. daily for 14 days
Trial: 31801679
Drug: TWHF 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TWHF 60 mg/d plus valsartan 160 mg/d
Trial: 23530837
Drug: Subcutaneous tissue
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous tissue closure with staples
Trial: 23530837
Drug: Subcutaneous tissue
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous tissue closure with intracutaneous sutures
Trial: 23530837
Drug: No subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No subcutaneous tissue closure with staples
Trial: 23530837
Drug: No subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No subcutaneous tissue closure with intracutaneous sutures
Trial: 21632811
Drug: Early metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early metformin (study years 1-4; age 8-12 years)
Trial: 21632811
Drug: Late metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late metformin (year 6; age 13-14 years)
Trial: 10632907
Drug: Single injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single injection (Group S)
Trial: 10632907
Drug: Multiple fractionated
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple fractionated doses (Group M)
Trial: 28263288
Drug: Non-adjuvanted influenza
RxNorm normalized name: Influenza, adjuvanted, quadrivalent, PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-adjuvanted influenza vaccine
Trial: 15846270
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (n = 530)
Trial: 12224004
Drug: Liposomal daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal daunorubicin (DaunoXome) combined with high-dose arabinosyl cytosine (HDAC)
Trial: 9626770
Drug: Chimeric anti-CD4
RxNorm normalized name: CHIMERIC ANTI-DISIALOGANGLIOSIDE (GD2) MONOCLONAL ANTIBODY (CH14.18/CHO)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chimeric anti-CD4 antibody treatment
Trial: 9039623
Drug: Dynamic contrast-enhanced
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dynamic contrast-enhanced MR imaging with gadolinium‐diethylenetriamine penta‐acetic acid (Gd‐DTPA) at a dosage of 0.1 mmol/kg body weight.
Trial: 9039623
Drug: MR imaging
RxNorm normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MR imaging follow-up during therapy in patients with B-CLL.
Trial: 4812364
Drug: Aspirin 15
RxNorm normalized name: aspirin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 15 mg/kg per dose for 5 doses
Trial: 4812364
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (open arteriotomy or no aspirin)
Trial: 23884826
Drug: Ephedrine bolus
RxNorm normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ephedrine bolus 5 mg plus ephedrine infusion
Trial: 23884826
Drug: Ephedrine bolus
RxNorm normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ephedrine bolus 5 mg plus normal saline infusion
Trial: 19666643
Drug: candesartan 8
RxNorm normalized name: candesartan 8 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: candesartan 8 mg/day
Trial: 15165934
Drug: candesartan 16
RxNorm normalized name: candesartan 16 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: candesartan 16 mg/day
Trial: 15848527
Drug: mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: mycophenolate mofetil (MMF), prednisone, daclizumab, and reduced CsA dose (5 mg per kg per day for 7 months followed by complete withdrawal)
Trial: 15848527
Drug: normal CsA
RxNorm normalized name: CsA
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal CsA dose (10 mg per kg per day adjusted according to C2 levels), MMF, prednisone, and no daclizumab
Trial: 11548984
Drug: Interferon beta‐1a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon beta‐1a (Rebif) 44 mcg subcutaneously three times per week
Trial: 11548984
Drug: Interferon beta‐1a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon beta‐1a (Rebif) 22 mcg subcutaneously three times per week
Trial: 9505784
Drug: Dexamethasone 10
RxNorm normalized name: dexamethasone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 10 mg (group D)
Trial: 3275748
Drug: Intraoperative radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative radiotherapy (IORT) to 20 Gy using high‐energy electrons followed by low‐dose (35 to 40 Gy) postoperative external beam irradiation
Trial: 3275748
Drug: High‐dose (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High‐dose (50 to 55 Gy) postoperative external beam irradiation
Trial: 22483593
Drug: Ultrasound-guided subacromial
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided subacromial injection with triamcinolone 40mg
Trial: 12017396
Drug: nimesulide-beta-cyclodextrin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nimesulide-beta-cyclodextrin (400 mg BID, orally = 100 mg nimesulide BID)
Trial: 10492407
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine and 10 mg preservative-free pethidine (group LP)
Trial: 10492407
Drug: 2% lidocaine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine, 10 mg preservative-free pethidine and 20 mg tenoxicam (group LPT)
Trial: 8934067
Drug: Uniplant contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uniplant contraceptive implant
Trial: 30413181
Drug: Daily low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily low-dose antibiotics
Trial: 24852946
Drug: Erythritol candy
RxNorm normalized name: Erythritol
DrugBank: Erythritol (DB04481)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythritol candy (7.5 g daily intake)
Trial: 24852946
Drug: Xylitol candy
RxNorm normalized name: Xylitol
DrugBank: Xylitol (DB11195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Xylitol candy (7.5 g daily intake)
Trial: 24852946
Drug: Sorbitol candy
RxNorm normalized name: Sorbitol
DrugBank: Sorbitol (DB01638)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorbitol candy (7.5 g daily intake)
Trial: 22381809
Drug: Tacrolimus and
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus and prednisone dual therapy
Trial: 17609246
Drug: IVF treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVF treatment
Trial: 110212
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 mg daily (A‐50)
Trial: 110212
Drug: Atenolol 100
RxNorm normalized name: atenolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 100 mg daily (A‐100)
Trial: 30851050
Drug: Both toothpaste
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both toothpaste formulations
Trial: 26285327
Drug: Intravenous laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous laser irradiation of the blood in addition to traditional medicamental treatment (n = 102)
Trial: 26285327
Drug: Traditional medicamental
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional medicamental treatment alone (Control group, n = 30)
Trial: 15100337
Drug: Guideline implementation
RxNorm normalized name: LARYNGEAL GUIDEWIRE,PROVOX #7215
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline implementation intervention including a tutorial for intake clinicians, group and individual performance feedback, use of a modified vital signs stamp, offer of free nicotine replacement therapy, and proactive telephone counseling.
Trial: 9364699
Drug: Virosome-formulated influenza
RxNorm normalized name: influenza, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virosome-formulated influenza vaccine
Trial: 9364699
Drug: Subunit influenza
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subunit influenza vaccine
Trial: 2388129
Drug: VK1 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VK1 (20 mg orally)
Trial: 2388129
Drug: VK2 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VK2 (20 mg orally)
Trial: 2388129
Drug: VK1 and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VK1 and VK2 (20 mg orally)
Trial: 6790990
Drug: Control preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control preparation (nonactivated prothrombin-complex concentrate)
Trial: 31116187
Drug: 5 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 × 5 mm dental implants with a nanostructured calcium‐incorporated titanium surface
Trial: 31116187
Drug: 10-mm or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-mm or longer implants in augmented bone
Trial: 31116187
Drug: Short implants
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short implants in mandibles
Trial: 31116187
Drug: Short implants
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short implants in maxillae
Trial: 22198635
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 1-mg reproterol and 2-mg disodium cromoglycate (DSCG)
Trial: 22198635
Drug: Short-acting β-agonist
RxNorm normalized name: Short-acting sulfonamides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-acting β-agonist reproterol alone
Trial: 18449549
Drug: 400 microg
RxNorm normalized name: Fentanyl 400 microgram buccal film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 microg of misoprostol vaginally (self administered) 4‐6 h prior to hysteroscopy
Trial: 17697036
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g paracetamol plus 30 mg dextromethorphan
Trial: 15370724
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg tropisetron daily intravenous bolus injection for 5 days
Trial: 1482431
Drug: Preincisional lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preincisional lidocaine infiltration (1% lidocaine, 40 mL)
Trial: 1482431
Drug: Postincisional lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postincisional lidocaine infiltration (1% lidocaine, 40 mL)
Trial: 2861315
Drug: Naloxone (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (0.4 to 1.2 mg intravenously)
Trial: 2861315
Drug: Placebo (vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (vehicle for injection)
Trial: 30404626
Drug: Dasatinib (SRC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib (SRC inhibitor)
Trial: 24811331
Drug: Acetazolamide (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide (2 × 250 mg/d)
Trial: 20095796
Drug: Lapatinib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib plus paclitaxel (L + P)
Trial: 12041767
Drug: Imipenem/cilastatin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem/cilastatin (2 or 4 g/day)
Trial: 24126967
Drug: Minimal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal treatment comparator (MTC)
Trial: 21130362
Drug: Biofeedback therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biofeedback therapy (3 weeks duration)
Trial: 9648697
Drug: Bla g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bla g 1 (cockroach allergen)
Trial: 9648697
Drug: Bla g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bla g 2 (cockroach allergen)
Trial: 31564452
Drug: Knowledge about
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Knowledge about vaccines recommended for HCWs
Trial: 31564452
Drug: Knowledge about
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Knowledge about hepatitis B and influenza vaccines
Trial: 31564452
Drug: Prior receipt
RxNorm normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior receipt of all recommended vaccines
Trial: 18324410
Drug: Glycerol and
RxNorm normalized name: Glycerol and honey only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycerol and icthammol (G&I) ribbon gauze
Trial: 18324410
Drug: Topical antibiotic
RxNorm normalized name: Tetracycline and derivatives, topical antibiotics
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical antibiotic and steroid drops
Trial: 11821506
Drug: Daily hemodialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily hemodialysis
Trial: 1703746
Drug: Ampicillin-chloramphenicol combination
RxNorm normalized name: Chloramphenicol
DrugBank: Chloramphenicol succinate (DB07565)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ampicillin-chloramphenicol combination
Trial: 23155345
Drug: Activated carbon
RxNorm normalized name: Activated carbon
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated carbon nanoparticles suspension (ACNS), 1 mL subserosal injection in a 4-quadrant region around the mass.
Trial: 23155345
Drug: Methylene blue
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylene blue (MB), 2 mL injected into the isolated, stretched and fixed vessel after specimen removal.
Trial: 16483177
Drug: 0.125 mg
RxNorm normalized name: digoxin 0.125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125 mg ganirelix sc daily for 7 days